Description: Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.
Home Page: www.sironabiochem.com
SBM Technical Analysis
595 Burrard Street
Vancouver,
BC
V7X 1L4
Canada
Phone:
604 641 4466
Officers
| Name | Title |
|---|---|
| Dr. Howard J. Verrico M.D., Ph.D. | Founder, Chairman, CEO & Sec. |
| Mr. Christopher D. Hopton C.G.A., C.P.A. | CFO & Director |
| Dr. Géraldine Deliencourt-Godefroy Ph.D. | Chief Scientific Officer & Director |
| Ms. Michelle Seltenrich MBA | VP of Operations |
| Dr. Brett A. Premack Ph.D. | Scientific Consultant |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 41.6366 |
| Price-to-Sales TTM: | 49.7008 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |